PRESS

Nov, 2018 - Press
TG Therapeutics announces Phase I study of novel BTK inhibitor, TG-1701, in patients with relapsed or refractory B-cell malignancies, is open for Enrollment  Read More

Jan, 2018 - Press
TG Therapeutics and Jiangsu Hengrui announce agreement for BTK inhibitor program for treatment of hematologic malignancies  Read More
​